Actinium Pharmaceuticals (ATNM) 10-K 25 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 25, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	ACTINIUM PHARMACEUTICALS, INC.
Trading Symbol	ATNM
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		22,143,974
Entity Public Float			$ 138,622,140
Amendment Flag	false
Entity Central Index Key	0001388320
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-52446
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	74-2963609
Entity Address, Address Line One	275 Madison Avenue, 7th Fl.
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10016
City Area Code	(646)
Local Phone Number	677-3870
Title of 12(b) Security	Common stock, par value $0.001
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
Auditor Name	Marcum llp
Auditor Location	Houston, Texas
Auditor Firm ID	688

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 77,829	$ 63,560
Restricted cash – current	392	48
Security deposit	50
Prepaid expenses and other current assets	1,478	1,317
Total Current Assets	79,749	64,925
Property and equipment, net of accumulated depreciation of $335 and $291	340	312
Operating lease right-of-use assets	241	579
Finance leases right-of-use assets	58	140
Security deposit		50
Restricted cash		391
Total Assets	80,388	66,397
Current Liabilities:
Accounts payable and accrued expenses	5,535	4,340
Other liability	998
Operating leases current liability	245	342
Finance leases current liability	62	85
Total Current Liabilities	6,840	4,767
Long-term operating lease obligations		245
Long-term finance lease obligations	3	66
Total Liabilities	6,843	5,078
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value; 1,000,000,000 and 600,000,000 shares authorized; 22,143,974 and 17,532,893 shares issued and outstanding	22	18
Additional paid-in capital	329,271	292,275
Accumulated deficit	(255,748)	(230,974)
Total Stockholders’ Equity	73,545	61,319
Total Liabilities and Stockholders’ Equity	$ 80,388	$ 66,397

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Property and equipment, net of accumulated depreciation (in Dollars)	$ 335	$ 291
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	600,000,000
Common stock, shares issued	22,143,974	17,532,893
Common stock, shares outstanding	22,143,974	17,532,893

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue
Revenue
Other Revenue	1,144
Total revenue	1,144
Operating expenses:
Research and development, net of reimbursements	18,031	16,085
General and administrative	8,077	6,308
Total operating expenses	26,108	22,393
Loss from operations	(24,964)	(22,393)
Other income:
Interest income - net	190	178
Total other income	190	178
Net loss	(24,774)	(22,215)
Deemed dividend for warrant down-round protection provision		(1)
Net loss applicable to common stockholders	$ (24,774)	$ (22,216)
Net loss per common share - basic and diluted (in Dollars per share)	$ (1.2)	$ (1.83)
Weighted average common shares outstanding - basic and diluted (in Shares)	20,568,373	12,134,259

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 5	$ 214,397	$ (208,758)	$ 5,644
Balance (in Shares) at Dec. 31, 2019	5,490,038
Stock-based compensation		1,254		1,254
Stock-based compensation (in Shares)	6,262
Sale of common stock and warrants, net of offering costs	$ 9	76,580		76,589
Sale of common stock and warrants, net of offering costs (in Shares)	8,575,051
Issuance of common stock from exercise of pre-funded warrants	$ 4	6		10
Issuance of common stock from exercise of pre-funded warrants (in Shares)	3,458,929
Issuance of common stock from exercise of warrants		37		37
Issuance of common stock from exercise of warrants (in Shares)	2,613
Deemed dividend for warrant down-round protection provision		1	(1)
Net loss			(22,215)	(22,215)
Balance at Dec. 31, 2020	$ 18	292,275	(230,974)	61,319
Balance (in Shares) at Dec. 31, 2020	17,532,893
Stock-based compensation		1,694		1,694
Stock-based compensation (in Shares)	21,306
Sale of common stock, net of offering costs	$ 4	35,296		35,300
Sale of common stock, net of offering costs (in Shares)	4,588,875
Issuance of common stock from exercise of stock options		6		6
Issuance of common stock from exercise of stock options (in Shares)	900
Net loss			(24,774)	(24,774)
Balance at Dec. 31, 2021	$ 22	$ 329,271	$ (255,748)	$ 73,545
Balance (in Shares) at Dec. 31, 2021	22,143,974

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net loss	$ (24,774)	$ (22,215)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,694	1,254
Depreciation and amortization expense	524	447
Prepaid expenses and other current assets	(161)	(531)
Increase (decrease) in:
Accounts payable and accrued expenses	1,195	(257)
Other liability	998
Operating lease liabilities	(342)	(315)
Net Cash Used In Operating Activities	(20,866)	(21,617)
Cash Flows from Investing Activities:
Purchase of property and equipment	(133)	(253)
Net Cash Used In Investing Activities	(133)	(253)
Cash Flows from Financing Activities:
Payments on note payable		(381)
Payments on finance leases	(85)	(79)
Proceeds from sales of shares of common stock and warrants, net of offering costs	35,300	76,589
Proceeds from the exercise of stock options	6
Proceeds from the exercise of warrants		47
Net Cash Provided By Financing Activities	35,221	76,176
Net change in cash, cash equivalents and restricted cash	14,222	54,306
Cash, cash equivalents and restricted cash at beginning of year	63,999	9,693
Cash, cash equivalents and restricted cash at end of year	78,221	63,999
Supplemental disclosures of cash flow information:
Cash paid for interest		8
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend for warrant down-round protection provision		$ 1

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Description of Business and Summary of Significant Accounting Policies	Note 1 - Description of Business and Summary of Significant Accounting Policies Nature of Business - Principles of Consolidation - Use of Estimates in Financial Statement Presentation - Impact of COVID–19 Pandemic on Financial Statements - Many countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. Accordingly, the Company’s ability to continue to operate its business may also be limited. Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect the Company’s business, financial condition and results of operations. In response to COVID-19, the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development or drug production of our drug candidates. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company’s business and the value of the Company’s common stock. Additionally, COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB’s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees. To date, COVID-19 has not had a financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts of COVID-19 will last or to what degree further disruption might impact the Company’s operations and financial results. Cash and Cash Equivalents and Restricted Cash- Following is a summary of cash, cash equivalents and restricted cash at December 31, 2021 and December 31, 2020: (in thousands) December 31, December 31, Cash and cash equivalents $ 77,829 $ 63,560 Restricted cash – current 392 48 Restricted cash – long-term - 391 Cash, cash equivalents and restricted cash $ 78,221 $ 63,999 Current restricted cash of $392 thousand at December 31, 2021 relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company’s lease for corporate office space. This restricted cash was classified as long-term restricted cash at December 31, 2020. Current restricted cash of $48 thousand at December 31, 2020 related to a credit card account. Property and Equipment - Leases Fair Value of Financial Instruments - Revenue Recognition Revenue From Contracts With Customers At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and (ii) the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the contract). The Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company’s estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. ASC 606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input method. Collaborative Arrangements - The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows the guidance of ASC 606 . Grant Revenue – Research and Development Costs - Share-Based Payments - Income Taxes - FASB ASC 740 prescribes guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meet a “more-likely-than-not” recognition threshold to be recognized. There were no tax positions for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year. The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses Net Loss Per Common Share For the years ended December 31, 2021 and 2020, the Company’s potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive. (in thousands) December 31, December 31, Options 1,362 815 Warrants 2,112 2,113 Total 3,474 2,928 Subsequent Events Accounting Standards Recently Adopted Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Accounting Standards Recently Issued– Earnings Per Share (topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718) and Derivatives and Hedging – Contracts in an Entity’s Own Equity (Subtopic 815-40) – Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options In October 2021, FASB issued ASU 2021-08, Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
Prepaid Expenses and Other Current Assets	Note 2 - Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following at December 31, 2021 and 2020: December 31, December 31, 2021 2020 Prepaid insurance $ 874 $ 792 Prepaid clinical trial expenses 543 457 Other prepaid expenses and other current assets 61 68 Total prepaid expenses and other current assets $ 1,478 $ 1,317

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 3 - Property and Equipment Property and equipment consisted of the following at December 31, 2021 and 2020: December 31, December 31, (in thousands) Lives 2021 2020 Lab equipment 5 years $ 476 $ 378 Office equipment and furniture 3 - 7 years 199 225 Less: accumulated depreciation (335 ) (291 ) Property and equipment, net $ 340 $ 312 Depreciation expense consisted of the following for the years ended December 31, 2021 and 2020, respectively: December 31, December 31, (in thousands) 2021 2020 Research and development $ 88 $ 36 General administrative 17 18 Total Depreciation expense $ 105 $ 54

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Note 4 - Leases The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with initial terms of 12 months or less. Right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company’s leases, the incremental borrowing rate was used based on the information available at commencement date in determining the present value of lease payments. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority of the Company’s leases as the reasonably certain threshold is not met. At December 31, 2021, the Company has an operating lease for corporate office space and two finance leases for office equipment and furniture located in the corporate office space. In addition, the Company has auxiliary corporate office space that it rents on a month-to-month basis; this rental is accounted for as an operating lease with the same term as the Company’s main office in the same building. The components of lease expense are as follows: (in thousands) Year ended Year ended Operating lease expense $ 372 $ 372 Finance lease cost Amortization of right-to-use assets $ 81 $ 81 Interest on lease liabilities $ 9 $ 16 Total finance lease cost 90 $ 97 Supplemental cash flow information related to leases are as follows: Year ended (in thousands) December 31, December 31, Cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow use from operating leases $ 377 $ 375 Operating cash flow use from finance leases $ 9 $ 16 Financing cash flow use from finance leases $ 85 $ 78 Non-cash activity: Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ 83 Finance Leases $ - $ - Weighted average remaining lease terms are as follows at December 31, 2021: Weighted average remaining lease term: Operating leases 0.6 years Finance Leases 0.8 years As the interest rate implicit in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate based on the information available in determining the present value of lease payments. The Company’s incremental borrowing rate was based on the term of the lease, the economic environment of the lease and reflect the rate the Company would have had to pay to borrow on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated: Weighted average discount rates: Operating leases 8 % Finance Leases 8 % Maturities of lease liabilities are as follows: Year ending December 31, Operating Finance 2022 252 64 2023 - 4 Total lease payments $ 252 $ 68 Less imputed interest (7 ) (3 ) Present value of lease liabilities $ 245 $ 65

Other revenue

Other revenue	12 Months Ended
	Dec. 31, 2021
Other Revenue [Abstract]
Other revenue	Note 5 - Other revenue The Company has a grant from a government-sponsored entity for research and development related activities that provide for payments for reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognizes revenue from grants as it performs services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Revenue of $0.2 million was recognized during year ended December 31, 2021. The Company determined that certain collaborations with a third-party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules related to various research activities. The Company identified a single performance obligation to provide research services within each module for which the Company receives monetary consideration. The third-party can choose to proceed with each module or can terminate the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third-party’s ability to terminate the module. The consideration is recognized to revenue over each module and revenue recognized during the year ended December 31, 2021 was $0.9 million. Other liability consists of $1.0 million of deferred other revenue that is expected to be recognized during 2022.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 - Commitments and Contingencies On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (“FHCRC”) to build upon previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.

Equity

Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Equity	Note 7 - Equity On April 24, 2020, the Company issued and sold 4.3 million shares of common stock and 2.8 million pre-funded warrants to purchase shares of common stock. The price to the public in this offering for each share of common stock was $4.50 and for each pre-funded warrant was $4.497. Each pre-funded warrant had an exercise price of $0.003 per share and was exercisable immediately upon issuance. Gross proceeds from this offering were $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering were $29.1 million. During the year ended December 31, 2020, holders of all of the 2.8 million pre-funded April 2020 warrants exercised their warrants at $0.003 per share and received 2.8 million shares of common stock. On June 19, 2020, the Company issued and sold 1.9 million shares of common stock and 0.7 million pre-funded warrants to purchase shares of common stock. The price to the public in this offering for each share of common stock was $9.75 and for each pre-funded warrant was $9.747. Each pre-funded warrant had an exercise price of $0.003 per share and was exercisable immediately upon issuance. Gross proceeds from this offering were $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Net proceeds from this offering were $23.0 million. During the year ended December 31, 2020, holders of all of the 0.7 million pre-funded June 2020 warrants exercised their warrants at $0.003 per share and received 0.7 million shares of common stock. In August 2020, the Company entered into the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (“JonesTrading”), pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of common stock are offered pursuant to the Company’s shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. As of December 31, 2020, the Company had sold 2.1 million shares of common stock, resulting in gross proceeds of $22.6 million and net proceeds of $21.7 million. For the year ended December 31, 2021, the Company sold 4.6 million shares of common stock, resulting in gross proceeds of $36.5 million and net proceeds of $35.3 million. 2019 Amended and Restated Stock Plan In December 2019, the Company’s 2019 Stock Plan was established. The expiration date of the plan is October 18, 2029 and the total number of shares of the Company’s common stock available for grant to employees, directors and consultants of the Company was 333,333 shares. At the Company’s Annual Meeting of Stockholders held on November 18, 2020, its stockholders authorized an increase in the number of shares authorized under the plan, resulting in the number of shares authorized in the plan to be 3,083,333 shares. At the Company’s Annual Meeting of Stockholders held on November 9, 2021, its stockholders authorized an increase in the number of shares authorized under the plan, resulting in the number of shares authorized in the plan to be 5,833,333 shares. 2013 Amended and Restated Stock Plan In September 2013, the Company’s 2013 Stock Plan was established. The expiration date of the plan is September 9, 2023 and at the time of approval, the total number of shares of the Company’s common stock available for grant to employees, directors and consultants of the Company under the plan was 91,666 shares. After a number of amendments approved by stockholders, the number of shares authorized under the plan is 758,333 shares. 2013 Equity Incentive Plan In September 2013, the Company’s 2013 Equity Incentive Plan was established. The expiration date of the plan is September 9, 2023 and the total number of shares of the Company’s common stock available for grant to employees, directors and consultants of the Company under the plan was 15,000 shares. In December 2013, the shareholders of the Company approved the plan and increased the number of shares authorized under the plan to 33,333 shares. Stock Options Following is a summary of stock option activity for the years ended December 31, 2021 and 2020: (in thousands, except for per-share amount) Number of Weighted Weighted Aggregate Outstanding, January 1, 2020 380 35.10 7.88 155 Granted 458 9.99 Cancelled (23 ) 16.84 Outstanding, December 31, 2020 815 21.53 8.51 120 Granted 881 6.43 Exercised (1 ) 6.69 Cancelled (333 ) 18.78 Outstanding, December 31, 2021 1,362 12.45 8.69 - Exercisable, December 31, 2021 354 27.04 6.92 - During 2021, the Company granted its employees and members of the Board of Directors options to purchase 881 thousand shares of common stock with an exercise price ranging from $6.02 to $9.25 per share, a term of 10 years, and a vesting period from 4 to 4.2 years. The options have an aggregated fair value of $3.9 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 0.65% to 1.28% (2) expected life of 6 years, (3) expected volatility range from 79.8% to 85.1%, and (4) zero expected dividends. During 2020, the Company granted its employees and members of the Board of Directors options to purchase 458 thousand shares of common stock with an exercise price ranging from $6.63 to $12.41 per share, a term of 10 years, and a vesting period from 4 to 4.2 years. The options have an aggregated fair value of $3.2 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate range from 0.34% to 0.56% (2) expected life of 6 years, (3) expected volatility range from 83.6% to 85.5%, and (4) zero expected dividends. During the years ended December 31, 2021 and 2020, options to purchase 333 thousand and 23 thousand common shares were cancelled, respectively, upon the termination of employment. During 2021, 1 thousand options were exercised for shares of common stock. There were no exercises of options during 2020. The fair values of all options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31, 2021 was $4.9 million related to unvested options, which is expected to be expensed over a weighted average of 3.3 years. During 2021 and 2020, the Company recorded total option expense of $1.5 million and $1.2 million, respectively. Pre-funded Warrants As part of the April 2020 offering and the June 2020 offering, the Company issued pre-funded warrants. Each pre-funded warrant had an exercise price of $0.003 per share and was exercisable immediately upon issuance. The pre-funded warrants did not have an expiration date. During 2020 all the pre-funded warrants were exercised for shares of common stock. Warrants Following is a summary of warrant activities for the years ended December 31, 2021 and 2020: (in thousands, except for per-share amounts) Number of Weighted Weighted Aggregate Outstanding, January 1, 2020 2,871 20.71 2.95 301 Granted - - Exercised (2 ) 15.00 Cancelled (756 ) 20.99 Outstanding, December 31, 2020 2,113 20.55 2.76 362 Granted 1 8.30 Exercised - - Cancelled (2 ) 50.17 Outstanding, December 31, 2021 2,112 20.52 1.76 276 Exercisable, December 31, 2021 2,108 20.12 1.76 276 The Company has an outstanding warrant to purchase 1,907 shares of common stock, issued on March 14, 2017 to Sandesh Seth, the Company’s Chairman and Chief Executive Officer. The warrant included down-round protection up until it was amended on August 11, 2020. For warrants with down-round protection, a deemed dividend is recorded for the change in fair value of the warrants when the down-round provision is triggered. As a result of the April 2020 offering and June 2020 offering, the exercise price of the warrant was reset from $26.40 per share to $15.62 per share. The down-round protection provision in the above warrants created a deemed dividend to common stockholders of $1 thousand in the year ended December 31, 2020 which is reflected in the accompanying consolidated statement of operations and consolidated statement of changes in stockholders’ equity. On August 11, 2020, the Company and Mr. Seth agreed to amend the warrant to remove the anti-dilution provision that had been in the warrant. Accordingly, pursuant to the amendment, as of August 11, 2020, the exercise price of the warrant will no longer be subject to a proportional adjustment if and when the Company issues any shares of its common stock for a consideration less than the exercise price of the warrant. All other terms of the warrant remained the same. During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense related to warrants of $16 thousand and $13 thousand, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 8 - Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities at December 31, 2021 and 2020 are as follows: (in thousands) 2021 2020 Deferred tax assets: Net operating losses carry forward $ 36,405 $ 33,955 Share-based compensation 1,213 1,689 Research and development/orphan drug credits 14,536 12,638 Intangibles 10,426 7,873 Others 19 19 Less: valuation allowance (62,599 ) (56,174 ) Deferred tax assets, net $ - $ - The Company has recorded a valuation allowance of $62.6 million and $56.2 million against its deferred tax assets at December 31, 2021 and 2020 respectively, because management determined that it is not more-likely-than not that those assets will be realized. For federal income tax purposes, the Company has $163.0 million of unused net operating losses (“NOLs”) at December 31, 2021 available for carry forward to future years. NOLs of $120.8 million generated prior to 2018 will begin to expire if unused in 2022. NOLs generated in 2018 and later years of $42.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1, 2022. For state income tax purposes, the Company has $87.9 million of unused NOLs at December 31, 2021 available for carry forward to future years. These NOLs will begin to expire in 2034 if unused. The Company has federal research and development tax credits of $2.9 million at December 31, 2021 which will begin to expire in 2034 if unused and orphan drug credits of $11.6 million which will begin to expire in 2028 if unused. Federal and state tax laws impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company’s ability to utilize these carryforwards may be limited as a result of an ownership change which may have already happened or may happen in the future. Such an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the net operating losses available. The difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax losses for the year ended December 31, 2021 and 2020 are as follows: (in thousands) December 31, December 31, Federal statutory income taxes $ (5,202 ) (21.0 )% $ (4,665 ) (21.0 )% State income taxes (373 ) (1.5 )% 56 0.3 % Deferred true-up 562 2.3 % (64 ) (0.3 )% Research and development/orphan drug tax credit (1,898 ) (7.7 )% (1,766 ) (8.0 )% Other 486 2.0 % 202 0.9 % Change in valuation allowance 6,425 25.9 % 6,237 28.1 % Provision for income tax $ - - $ - -

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Nature of Business	Nature of Business -
Principles of Consolidation	Principles of Consolidation -
Use of Estimates in Financial Statement Presentation	Use of Estimates in Financial Statement Presentation -
Impact of COVID–19 Pandemic on Financial Statements	Impact of COVID–19 Pandemic on Financial Statements - Many countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. Accordingly, the Company’s ability to continue to operate its business may also be limited. Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect the Company’s business, financial condition and results of operations. In response to COVID-19, the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development or drug production of our drug candidates. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company’s business and the value of the Company’s common stock. Additionally, COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB’s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees. To date, COVID-19 has not had a financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts of COVID-19 will last or to what degree further disruption might impact the Company’s operations and financial results.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash- Following is a summary of cash, cash equivalents and restricted cash at December 31, 2021 and December 31, 2020: (in thousands) December 31, December 31, Cash and cash equivalents $ 77,829 $ 63,560 Restricted cash – current 392 48 Restricted cash – long-term - 391 Cash, cash equivalents and restricted cash $ 78,221 $ 63,999 Current restricted cash of $392 thousand at December 31, 2021 relates to a certificate of deposit held as collateral for a letter of credit issued in connection with the Company’s lease for corporate office space. This restricted cash was classified as long-term restricted cash at December 31, 2020. Current restricted cash of $48 thousand at December 31, 2020 related to a credit card account.
Property and Equipment	Property and Equipment -
Leases	Leases
Fair Value of Financial Instruments	Fair Value of Financial Instruments -
Revenue Recognition	Revenue Recognition Revenue From Contracts With Customers At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and (ii) the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the contract). The Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company’s estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. ASC 606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input method.
Collaborative Arrangements	Collaborative Arrangements - The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows the guidance of ASC 606 .
Grant Revenue	Grant Revenue –
Research and Development Costs	Research and Development Costs -
Share-Based Payments	Share-Based Payments -
Income Taxes	Income Taxes - FASB ASC 740 prescribes guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions must meet a “more-likely-than-not” recognition threshold to be recognized. There were no tax positions for which it is considered reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year. The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses
Net Loss Per Common Share	Net Loss Per Common Share For the years ended December 31, 2021 and 2020, the Company’s potentially dilutive shares, which include outstanding common stock options and warrants have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive. (in thousands) December 31, December 31, Options 1,362 815 Warrants 2,112 2,113 Total 3,474 2,928
Subsequent Events	Subsequent Events
Accounting Standards Recently Adopted	Accounting Standards Recently Adopted Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
Accounting Standards Recently Issued	Accounting Standards Recently Issued– Earnings Per Share (topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718) and Derivatives and Hedging – Contracts in an Entity’s Own Equity (Subtopic 815-40) – Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options In October 2021, FASB issued ASU 2021-08, Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance

Description of Business and S_2

Description of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of cash and cash equivalent and restricted cash	(in thousands) December 31, December 31, Cash and cash equivalents $ 77,829 $ 63,560 Restricted cash – current 392 48 Restricted cash – long-term - 391 Cash, cash equivalents and restricted cash $ 78,221 $ 63,999
Schedule of antidilutive securities excluded from computation of diluted net loss per share	(in thousands) December 31, December 31, Options 1,362 815 Warrants 2,112 2,113 Total 3,474 2,928

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
Schedule of prepaid expenses and other current assets	December 31, December 31, 2021 2020 Prepaid insurance $ 874 $ 792 Prepaid clinical trial expenses 543 457 Other prepaid expenses and other current assets 61 68 Total prepaid expenses and other current assets $ 1,478 $ 1,317

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, December 31, (in thousands) Lives 2021 2020 Lab equipment 5 years $ 476 $ 378 Office equipment and furniture 3 - 7 years 199 225 Less: accumulated depreciation (335 ) (291 ) Property and equipment, net $ 340 $ 312
Schedule of depreciation expense	December 31, December 31, (in thousands) 2021 2020 Research and development $ 88 $ 36 General administrative 17 18 Total Depreciation expense $ 105 $ 54

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of components of lease expense	(in thousands) Year ended Year ended Operating lease expense $ 372 $ 372 Finance lease cost Amortization of right-to-use assets $ 81 $ 81 Interest on lease liabilities $ 9 $ 16 Total finance lease cost 90 $ 97
Schedule of supplemental cash flow information related to leases	Year ended (in thousands) December 31, December 31, Cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow use from operating leases $ 377 $ 375 Operating cash flow use from finance leases $ 9 $ 16 Financing cash flow use from finance leases $ 85 $ 78 Non-cash activity: Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ 83 Finance Leases $ - $ -
Schedule of weighted average remaining lease terms	Weighted average remaining lease term: Operating leases 0.6 years Finance Leases 0.8 years
Schedule of weighted average discount rates	Weighted average discount rates: Operating leases 8 % Finance Leases 8 %
Schedule of maturities of lease liabilities	Year ending December 31, Operating Finance 2022 252 64 2023 - 4 Total lease payments $ 252 $ 68 Less imputed interest (7 ) (3 ) Present value of lease liabilities $ 245 $ 65

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of stock option activity	(in thousands, except for per-share amount) Number of Weighted Weighted Aggregate Outstanding, January 1, 2020 380 35.10 7.88 155 Granted 458 9.99 Cancelled (23 ) 16.84 Outstanding, December 31, 2020 815 21.53 8.51 120 Granted 881 6.43 Exercised (1 ) 6.69 Cancelled (333 ) 18.78 Outstanding, December 31, 2021 1,362 12.45 8.69 - Exercisable, December 31, 2021 354 27.04 6.92 -
Schedule of warrant activities	(in thousands, except for per-share amounts) Number of Weighted Weighted Aggregate Outstanding, January 1, 2020 2,871 20.71 2.95 301 Granted - - Exercised (2 ) 15.00 Cancelled (756 ) 20.99 Outstanding, December 31, 2020 2,113 20.55 2.76 362 Granted 1 8.30 Exercised - - Cancelled (2 ) 50.17 Outstanding, December 31, 2021 2,112 20.52 1.76 276 Exercisable, December 31, 2021 2,108 20.12 1.76 276

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	(in thousands) 2021 2020 Deferred tax assets: Net operating losses carry forward $ 36,405 $ 33,955 Share-based compensation 1,213 1,689 Research and development/orphan drug credits 14,536 12,638 Intangibles 10,426 7,873 Others 19 19 Less: valuation allowance (62,599 ) (56,174 ) Deferred tax assets, net $ - $ -
Schedule of difference between income tax provision and U.S federal statutory rates	(in thousands) December 31, December 31, Federal statutory income taxes $ (5,202 ) (21.0 )% $ (4,665 ) (21.0 )% State income taxes (373 ) (1.5 )% 56 0.3 % Deferred true-up 562 2.3 % (64 ) (0.3 )% Research and development/orphan drug tax credit (1,898 ) (7.7 )% (1,766 ) (8.0 )% Other 486 2.0 % 202 0.9 % Change in valuation allowance 6,425 25.9 % 6,237 28.1 % Provision for income tax $ - - $ - -

Description of Business and S_3

Description of Business and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Current restricted cash	$ 392	$ 48

Description of Business and S_4

Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash and cash equivalent and restricted cash - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of cash and cash equivalent and restricted cash [Abstract]
Cash and cash equivalents	$ 77,829	$ 63,560
Restricted cash – current	392	48
Restricted cash – long-term		391
Cash, cash equivalents and restricted cash	$ 78,221	$ 63,999

Description of Business and S_5

Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of antidilutive securities excluded from computation of diluted net loss per share - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,474	2,928
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,362	815
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,112	2,113

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses and other current assets [Abstract]
Prepaid insurance	$ 874	$ 792
Prepaid clinical trial expenses	543	457
Other prepaid expenses and other current assets	61	68
Total prepaid expenses and other current assets	$ 1,478	$ 1,317

Property and Equipment (Details

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (335)	$ (291)
Property and equipment, net	$ 340	312
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Property and equipment, gross	$ 476	378
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 199	$ 225
Minimum [Member] | Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Useful lives	3 years
Maximum [Member] | Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Useful lives	7 years

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of depreciation expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment (Details) - Schedule of depreciation expense [Line Items]
Total Depreciation expense	$ 105	$ 54
Research and development [Member]
Property and Equipment (Details) - Schedule of depreciation expense [Line Items]
Total Depreciation expense	88	36
General administrative [Member]
Property and Equipment (Details) - Schedule of depreciation expense [Line Items]
Total Depreciation expense	$ 17	$ 18

Leases (Details) - Schedule of

Leases (Details) - Schedule of components of lease expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of components of lease expense [Abstract]
Operating lease expense	$ 372	$ 372
Finance lease cost
Amortization of right-to-use assets	81	81
Interest on lease liabilities	9	16
Total finance lease cost	$ 90	$ 97

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of supplemental cash flow information related to leases - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow use from operating leases	$ 377	$ 375
Operating cash flow use from finance leases	9	16
Financing cash flow use from finance leases	85	78
Right-of-use assets obtained in exchange for lease obligations:
Operating leases		83
Finance Leases

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of weighted average remaining lease terms	Dec. 31, 2021
Weighted average remaining lease term:
Operating leases	7 months 6 days
Finance Leases	9 months 18 days

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of weighted average discount rates	Dec. 31, 2021
Weighted average discount rates:
Operating leases	8.00%
Finance Leases	8.00%

Leases (Details) - Schedule o_5

Leases (Details) - Schedule of maturities of lease liabilities $ in Thousands	Dec. 31, 2021USD ($)
Operating Leases [Member]
Leases (Details) - Schedule of maturities of lease liabilities [Line Items]
2022	$ 252
2023
Total lease payments	252
Less imputed interest	(7)
Present value of lease liabilities	245
Finance Leases [Member]
Leases (Details) - Schedule of maturities of lease liabilities [Line Items]
2022	64
2023	4
Total lease payments	68
Less imputed interest	(3)
Present value of lease liabilities	$ 65

Other revenue (Details)

Other revenue (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Other Revenue [Abstract]
Revenue	$ 0.2
Recognized to revenue	0.9
Deferred revenue	$ 1

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	1 Months Ended
	Jun. 15, 2012USD ($)
Commitments and Contingencies Disclosure [Abstract]
Milestone payment	$ 1
Description of royalty payment	Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Thousands

Apr. 24, 2020

Aug. 31, 2020

Jun. 19, 2020

Dec. 31, 2021

Dec. 31, 2020

Nov. 09, 2021

Nov. 18, 2020

Jun. 30, 2020

Apr. 30, 2020

Dec. 31, 2019

Mar. 14, 2017

Dec. 31, 2013

Sep. 30, 2013

Equity (Details) [Line Items]

Sale of common stock, shares

4,300,000

4,600,000

2,100,000

Warrants to purchase shares of common stock

2,800,000

Public offering each share of common stock (in Dollars per share)

$ 4.5

Each pre-funded warrant (in Dollars per share)

4.497

Exercise price of warrant (in Dollars per share)

$ 0.003

$ 0.003

$ 0.003

Gross proceeds (in Dollars)

$ 31,600

$ 36,500

$ 22,600

Net proceeds of public offering (in Dollars)

$ 29,100

Issuance of common stock

700,000

Pre-funded amount

700,000

Equity description

the Company entered into the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (“JonesTrading”), pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of common stock are offered pursuant to the Company’s shelf registration statement on Form S-3 filed with the SEC on August 7, 2020.

Net proceeds (in Dollars)

$ 35,300

$ 21,700

Stock option

881,000

458,000

Option exercise price minimum (in Dollars per share)

$ 6.02

$ 6.63

Option exercise price maximum (in Dollars per share)

$ 9.25

$ 12.41

Stock options, term

10 years

10 years

Aggregated fair value (in Dollars)

$ 3,200

Stock option cancelations

333,000

23,000

Exercised for shares of common stock

1,000

Unrecognized compensation expense (in Dollars)

$ 4,900

Vesting period

3 years 3 months 18 days

Compensation expense related to stock options (in Dollars)

$ 1,500

$ 1,200

Outstanding warrant to purchase shares of common stock, issued

1,907

Deemed dividend to common stockholders (in Dollars)

1

Stock based compensation expense warrants (in Dollars)

$ 16

$ 13

2013 Amended and Restated Stock Plan [Member]

Equity (Details) [Line Items]

Number of shares authorized

758,333

91,666

Equity Option [Member]

Equity (Details) [Line Items]

Aggregate fair value (in Dollars)

$ 3,900

Minimum [Member] | Equity Option [Member]

Equity (Details) [Line Items]

Vesting period

4 years

4 years

Maximum [Member] | Equity Option [Member]

Equity (Details) [Line Items]

Vesting period

4 years 2 months 12 days

4 years 2 months 12 days

Warrant [Member]

Equity (Details) [Line Items]

Exercise price of warrant (in Dollars per share)

$ 15.62

$ 26.4

2019 Amended and Restated Stock Plan [Member]

Equity (Details) [Line Items]

Number of shares authorized

5,833,333

3,083,333

333,333

2013 Equity Incentive Plan [Member]

Equity (Details) [Line Items]

Number of shares authorized

33,333

15,000

Pre-Funded Warrants [Member]

Equity (Details) [Line Items]

Exercise price of warrant (in Dollars per share)

$ 0.003

Gross proceeds (in Dollars)

$ 25,000

Net proceeds of public offering (in Dollars)

$ 23,000

Issuance of common stock

1,900,000

2,800,000

Warrant to purchase of common stock

700,000

Exercise price per share (in Dollars per share)

$ 0.003

Common Stock [Member]

Equity (Details) [Line Items]

Share price (in Dollars per share)

$ 9.75

Warrant [Member]

Equity (Details) [Line Items]

Share price (in Dollars per share)

$ 9.747

Equity (Details) - Schedule of

Equity (Details) - Schedule of stock option activity - Stock Option [Membe] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Equity (Details) - Schedule of stock option activity [Line Items]
Number of Options, Outstanding Beginning	815	380
Weighted Average Exercise Price, Outstanding Beginning	$ 21.53	$ 35.1
Weighted Average Remaining Contractual Term (in years), Outstanding Beginning		7 years 10 months 17 days
Aggregate Intrinsic Value, Outstanding Beginning		$ 155
Number of Options, Outstanding Ending	1,362	815
Weighted Average Exercise Price, Outstanding Ending	$ 12.45	$ 21.53
Weighted Average Remaining Contractual Term (in years), Outstanding Ending	8 years 8 months 8 days	8 years 6 months 3 days
Aggregate Intrinsic Value, Outstanding Ending		$ 120
Number of Options, Exercisable Ending	354
Weighted Average Exercise Price, Exercisable Ending	$ 27.04
Weighted Average Remaining Contractual Term (in years), Exercisable Ending	6 years 11 months 1 day
Number of Options, Granted	881	458
Weighted Average Exercise Price, Granted	$ 6.43	$ 9.99
Number of Options, Exercised	(1)
Weighted Average Exercise Price, Exercised	$ 6.69
Number of Options, Cancelled	(333)	(23)
Weighted Average Exercise Price, Cancelled	$ 18.78	$ 16.84

Equity (Details) - Schedule _2

Equity (Details) - Schedule of warrant activities - Warrant [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant [Line Items]
Number of Warrants, Outstanding, Beginning	2,113	2,871
Weighted Average Exercise Price, Beginning	$ 20.55	$ 20.71
Weighted average remaining contractual term (in years), beginning		2 years 11 months 12 days
Aggregate Intrinsic Value, Beginning	$ 362	$ 301
Number of Warrants, Outstanding, Ending	2,112	2,113
Weighted Average Exercise Price, Ending	$ 20.52	$ 20.55
Weighted Average Remaining Contractual Term (in years), Ending	1 year 9 months 3 days	2 years 9 months 3 days
Aggregate Intrinsic Value, Ending	$ 276	$ 362
Number of Warrants, Exercisable	2,108
Weighted Average Exercise Price, Exercisable	$ 20.12
Weighted Average Remaining Contractual Term (in years), Exercisable	1 year 9 months 3 days
Aggregate Intrinsic Value, Exercisable	$ 276
Number of Warrants, Granted	1
Weighted Average Exercise Price, Granted	$ 8.3
Number of Warrants, Exercised		(2)
Weighted Average Exercise Price, Exercised		$ 15
Number of Warrants, Cancelled/Expired	(2)	(756)
Weighted Average Exercise Price, Cancelled/Expired	$ 50.17	$ 20.99

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes (Details) [Line Items]
Deferred tax assets, valuation allowance	$ 62.6	$ 56.2
Federal income tax purposes, net operating losses	$ 163
Net operating losses, description	NOLs of $120.8 million generated prior to 2018 will begin to expire if unused in 2022. NOLs generated in 2018 and later years of $42.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1, 2022.
State income tax purposes, net operating losses		$ 87.9
Federal Research and Development Tax Credits [Member]
Income Taxes (Details) [Line Items]
Net operating loss expiration date	The Company has federal research and development tax credits of $2.9 million at December 31, 2021 which will begin to expire in 2034 if unused and orphan drug credits of $11.6 million which will begin to expire in 2028 if unused.
Net operating losses	$ 2.9
Orphan Drug Credits [Member]
Income Taxes (Details) [Line Items]
Net operating losses	$ 11.6

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating losses carry forward	$ 36,405	$ 33,955
Share-based compensation	1,213	1,689
Research and development/orphan drug credits	14,536	12,638
Intangibles	10,426	7,873
Others	19	19
Less: valuation allowance	(62,599)	(56,174)
Deferred tax assets, net

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of difference between income tax provision and U.S federal statutory rates - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of difference between income tax provision and U.S federal statutory rates [Abstract]
Federal statutory income taxes	$ (5,202)	$ (4,665)
Federal statutory income taxes, percentage	(21.00%)	(21.00%)
State income taxes	$ (373)	$ 56
State income taxes, percentage	(1.50%)	0.30%
Deferred true-up	$ 562	$ (64)
Deferred true-up, percentage	2.30%	(0.30%)
Research and development/orphan drug tax credit	$ (1,898)	$ (1,766)
Research and development/orphan drug tax credit, percentage	(7.70%)	(8.00%)
Other	$ 486	$ 202
Other, percentage	2.00%	0.90%
Change in valuation allowance	$ 6,425	$ 6,237
Change in valuation allowance, percentage	25.90%	28.10%
Provision for income tax
Provision for income tax, percentage